Drug intelligence / Profile preview

MVX-600

Development stage: Preclinical
Lead developer: MaveriX Oncology
Modality: Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

MVX-600 is a conditionally activated small molecule drug conjugate (CA-SMDC) being developed by MaveriX Oncology. It is designed to selectively deliver a nucleotide or nucleoside analog cytotoxic payload directly to tumor cells, minimizing systemic toxicity. The "conditionally activated" nature of the platform relies on the unique biochemical environment of the tumor microenvironment to trigger the release of the active drug. MVX-600 is currently in the IND-enabling/preclinical stage, with a primary focus on treating metastatic cancers, particularly metastatic colorectal cancer (mCRC).

Targets

DNA

Beyond the preview

Go deeper on MVX-600.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVX-600.

Explore the full profile